From Setback to Success TFS’s Strategic Rescue of a Struggling Onychomycosis Study

Download our case study to:

Discover the remarkable story of how TFS HealthScience managed to rescue a critical Phase III Onychomycosis study from failure. Navigating a complex landscape of protracted contractual negotiations, rigorous patient screening requirements, and an ineffective recruitment campaign, TFS managed to turn the tide and exceed client expectations.

Download this case study to discover how TFS’s strategic interventions significantly improved the study outcomes and strengthened the client’s relationships with the study sites. This transformational journey showcases our adaptability, strategic thinking, and unflinching dedication to quality, setting a powerful precedent for future projects. Explore how TFS turned challenges into opportunities, adding value to both the present research and future collaborations.

Learn more about our related services and resources:

TFS Dermatology

Connect with Us

Contact us today to discover how TFS can be your strategic CRO partner in clinical development.

Let's Talk

Learn More About Our Dermatology Expertise

Managing Placebo Risk in Dermatology TrialsWebinars

Managing Placebo Risk in Dermatology Trials

Gain practical strategies for managing placebo risk and ensuring credible, compliant dermatology trial results.
Global support for sponsors running psoriasis clinical trials
Top 5 Challenges in Psoriasis Clinical Trials (and How to Overcome Them)Article

Top 5 Challenges in Psoriasis Clinical Trials (and How to Overcome Them)

Psoriasis clinical trials face predictable hurdles, from patient recruitment shortfalls to regulatory complexity. This blog explores the five most common challenges and practical strategies sponsors can use to overcome them.
atopic dermatitis trial design
Emerging Therapies for Atopic DermatitisWhite paper

Emerging Therapies for Atopic Dermatitis

Learn more about next-generation clinical research in atopic dermatitis with insights into new therapeutic targets, disease endotyping, and smarter trial design.